Drugs / JECEVAX
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03204227 | Jun → Aug 2017 | Japanese encephalitis | National Institute of Hygiene and Epidemiology, Vietnam | Completed | No outcome recorded |
| Phase 2 | NCT02816554 | Apr → Sep 2015 | Japanese encephalitis | National Institute of Hygiene and Epidemiology, Vietnam | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03282370 | Sep 2017 → Feb 2018 | Japanese encephalitis | National Institute of Hygiene and Epidemiology, Vietnam | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JECEVAX | “JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days” NCT02816554 ↗ |
| Known as | JECEVAX- VABIOTECH-Vietnam | “the studied vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine” NCT02816554 ↗1“the study vaccine (JECEVAX- VABIOTECH-Vietnam)” NCT03204227 ↗ |
| Modality | Vaccine | “Inactivated Japanese Encephalitis Vaccine (JECEVAX)” NCT02816554 ↗ |
| Route | Subcutaneous | “Subcutaneous injection 0.5ml/dose” NCT02816554 ↗ |